YB-811 / Ymmunobio - LARVOL DELTA

YB-811, a novel antibody drug conjugate targeting the tumor-selective human neuronal pentraxin receptor shows pronounced efficacy in experimental tumor models (AACR 2026) - "Recent immunohistochemistry studies performed with a fully humanized monoclonal antibody (YB-800) targeting NPTXR with high affinity have revealed expression of membrane-associated NPTXR protein in a wide variety of solid tumors (but not in adjacent healthy tissues and healthy tissue samples) with a high prevalence (up to 98%) and H-scores (up to 300); e.g., in bladder, cervix, non-TNBC, NSCLC, and pancreas tumor samples. Results clearly indicate concentration- and time-dependent effect on tumor cell proliferation and survival, as well as pronounced anti-tumor activity - tumor growth inhibition/regression - in established tumor-bearing athymic mice. Taken together, these results strongly support further exploration of the potential therapeutic benefit of YB-811."

ADC • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer

YB-800 ADCs Reach Important Milestone: Proof of Concept in Preclinical in Vitro and in Vivo Tests (PRNewswire) - "Ymmunobio AG...is proud to announce that its two-antibody drug conjugate (ADC) assets, YB-800ADC1 and YB-800ADC2, have completed the preclinical proof of concept studies. Both in vivo and in vitro studies have reached this important milestone by demonstrating the anti-tumor efficacy of both ADCs....The ADCs are derived from YB's lead antibody YB-800 which targets a novel and first in class tumor marker. They utilize established payloads and a third-generation linker, demonstrating a tumor growth inhibition of 90%."

Preclinical • Solid Tumor